Mira Pharmaceuticals reported revenue of $0.22M and net income of -$5.98M for the quarter ended Dec 2025, up 465.9% year over year. This income statement covers 15 quarters of results from Jun 2022 through Dec 2025, standardized by Business Quant from the company’s SEC filings.
| Income StatementIncome Statement | Jun2022 | Sep2022 | Dec2022 | Mar2023 | Jun2023 | Sep2023 | Dec2023 | Mar2024 | Jun2024 | Sep2024 | Dec2024 | Mar2025 | Jun2025 | Sep2025 | Dec2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue & cost | |||||||||||||||
| Revenue | 0.04M | 0.04M | 0.01M | 0.13M | 0.22M | ||||||||||
| Operating items | |||||||||||||||
| Research & DevelopmentR&D | 0.71M | 0.88M | 0.27M | 1.02M | 0.39M | 0.76M | 0.61M | 1.07M | 0.86M | 0.31M | 0.50M | 0.41M | 0.50M | ||
| Selling, General & AdministrativeSG&A | 1.59M | 0.74M | 0.05M | 0.61M | 1.07M | 2.14M | 2.67M | 1.01M | 1.12M | 1.01M | 1.58M | 1.49M | 1.05M | 0.90M | 5.33M |
| Other Operating ExpensesOther Opex | 0.83M | 0.36M | 0.41M | 0.45M | -0.10M | ||||||||||
| Operating ExpensesOpex | 2.42M | 1.81M | 1.35M | 1.34M | 0.97M | 3.16M | 3.06M | 1.77M | 1.73M | 2.08M | 2.44M | 1.81M | 1.55M | 1.32M | 5.82M |
| Non-operating items | |||||||||||||||
| Non Operating Interest Expenses | 0.00M | 0.00M | 0.00M | 0.00M | 0.30M | 0.43M | 2.73M | -0.05M | -0.04M | -0.04M | -0.02M | ||||
| Non Operating Investment IncomeNon-Op. Investment Inc. | 0.18M | -0.21M | |||||||||||||
| Interest & Investment IncomeInt & Inv Inc | 0.04M | 0.01M | |||||||||||||
| Other Non Operating IncomeOther Non Op Inc. | -107.00 | 0.01M | 0.05M | ||||||||||||
| Non Operating IncomeNon Op. Inc. | 0.04M | 0.04M | 0.18M | -0.16M | |||||||||||
| Net income details | |||||||||||||||
| Income towards Parent CompanyParent Net Inc | -2.42M | -1.81M | -1.35M | -1.34M | -1.27M | -3.59M | -5.79M | -1.72M | -1.69M | -2.04M | -2.40M | -1.78M | -1.54M | -1.14M | -5.94M |
| Preferred Dividend PaymentsPref Dividends | 21.56M | ||||||||||||||
| Net Income towards Common StockholdersNet Income | -2.42M | -1.81M | -1.35M | -1.34M | -1.27M | -3.59M | -5.79M | -1.72M | -1.69M | -2.04M | -2.40M | -1.78M | -1.54M | -22.69M | -5.98M |
| Additional items | |||||||||||||||
| EPS (Basic) | -0.19 | -0.14 | -0.08 | -0.08 | -0.10 | -0.26 | -0.31 | -0.09 | -0.11 | -0.14 | -0.16 | -0.11 | -0.09 | -1.18 | -0.25 |
| EPS (Diluted) | -0.19 | -0.14 | -0.08 | -0.08 | -0.10 | -0.26 | -0.31 | -0.09 | -0.11 | -0.14 | -0.16 | -0.11 | -0.09 | -1.18 | -0.31 |
| Shares Outstanding | 13.09M | 13.17M | 17.57M | 17.75M | 13.31M | 13.64M | 18.57M | 19.71M | 14.78M | 15.07M | 15.44M | 16.65M | 16.99M | 19.27M | 23.69M |
| Shares Outstanding (Diluted)Shares Outstanding (Dil.) | 13.09M | 13.17M | 17.57M | 17.75M | 13.31M | 13.64M | 18.57M | 19.71M | 14.78M | 15.07M | 15.44M | 16.65M | 16.99M | 19.27M | 19.27M |
| Shares Outstanding (Entity)Shares Outstanding (Entity.) | 13.08M | 13.26M | 17.57M | 17.75M | 13.31M | 14.78M | 18.57M | 19.71M | 14.78M | 16.27M | 16.56M | 16.81M | 17.39M | 19.27M | 23.69M |
| Interest ExpensesInt Expense | 0.00M | 0.00M | 0.00M | 0.00M | 0.30M | 0.43M | 2.73M | -0.05M | -0.04M | -0.04M | -0.02M |
Pull Mira Pharmaceuticals's standardized financial statements into your own models, spreadsheets and apps with the Business Quant Financial Statements API. The request below follows the statement, frequency and period selected above. Swap YOUR_API_KEY for your own key.
https://data.businessquant.com/statements?ticker=MIRA&statement=IS&frequency=Quarter&period=all&api_key=YOUR_API_KEYimport requests
url = "https://data.businessquant.com/statements"
params = {"ticker": "MIRA", "statement": "IS", "frequency": "Quarter", "period": "all", "api_key": "YOUR_API_KEY"}
data = requests.get(url, params=params).json()const res = await fetch("https://data.businessquant.com/statements?ticker=MIRA&statement=IS&frequency=Quarter&period=all&api_key=YOUR_API_KEY");
const data = await res.json();